An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT04189614. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
Study identification
- NCT ID
- NCT04189614
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 65 participants
Conditions and interventions
Conditions
Interventions
- Cofetuzumab Pelidotin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 12, 2020
- Primary completion
- Apr 30, 2026
- Completion
- Apr 30, 2026
- Last update posted
- Mar 23, 2026
2020 – 2026
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham - Main /ID# 213605 | Birmingham | Alabama | 35233 | — |
| Highlands Oncology Group, PA /ID# 215383 | Springdale | Arkansas | 72762 | — |
| Duplicate_Stanford University School of Med /ID# 213450 | Stanford | California | 94305-2200 | — |
| Univ of Colorado Cancer Center /ID# 215295 | Aurora | Colorado | 80045 | — |
| Sylvester Comprehensive Cancer Center /ID# 216433 | Miami | Florida | 33136-1002 | — |
| Moffitt Cancer Center /ID# 215101 | Tampa | Florida | 33612-9416 | — |
| Washington University-School of Medicine /ID# 213453 | St Louis | Missouri | 63110 | — |
| The Ohio State University /ID# 211088 | Columbus | Ohio | 43210 | — |
| Tennessee Oncology, PLLC /ID# 215326 | Nashville | Tennessee | 37203 | — |
| Oncology Consultants /ID# 215932 | Houston | Texas | 77030-3306 | — |
| University of Texas MD Anderson Cancer Center /ID# 215876 | Houston | Texas | 77030 | — |
| Virginia Cancer Specialists - Fairfax /ID# 216427 | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04189614, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 23, 2026 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04189614 live on ClinicalTrials.gov.